<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02984423</url>
  </required_header>
  <id_info>
    <org_study_id>D0817R00002</org_study_id>
    <nct_id>NCT02984423</nct_id>
  </id_info>
  <brief_title>FLABRA: Frontline Approach for BRCA Testing in OC Treatment naïve Population. A LATIN AMERICA Epidemiologic Study</brief_title>
  <acronym>FLABRA</acronym>
  <official_title>Frontline Approach for BRCA Testing in OC Treatment naïve Population. A LATIN AMERICA Epidemiologic Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to answer very important questions regarding the prevalence of somatic and&#xD;
      germline mutations (sBRCAm and gBRCAm) in a population of newly diagnosed ovarian cancer&#xD;
      patients from Latin America. These answers may be extremely helpful in the counseling for&#xD;
      genetic risk and treatment approach in these populations and will aid in making treatment&#xD;
      decisions in the future&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      FLABRA is a cross-sectional, multi-center, epidemiological observational study designed to&#xD;
      evaluate the prevalence of BRCA mutations in newly diagnosed ovarian cancer patients across&#xD;
      understudied ethnic groups in Latin America. Secondary objectives of the study are to&#xD;
      evaluate the prevalence of sBRCAm versus gBRCAm in newly diagnosed ovarian cancer patients&#xD;
      and to describe current ovarian cancer counselling and treatment approach patterns at front&#xD;
      line setting across Latin America.&#xD;
&#xD;
      In the Screening Visit, consecutive eligible patients who have been newly diagnosed with&#xD;
      ovarian cancer within the last 120 days will be invited to participate. After having provided&#xD;
      consent, patients will be asked to provide ethnicity and cancer family history information.&#xD;
      Patients will self-identify to one or more of the defined broad ethnic groups (Native&#xD;
      American, Afro-Caribbean, Caucasian) based on self-reported ancestry information. Archived&#xD;
      tumor blocks or twenty 10-µm sections from eligible patients will be requested from the local&#xD;
      pathology lab and used for BRCA mutations testing.&#xD;
&#xD;
      Patient medical records will be reviewed for data relevant to the ovarian cancer diagnosis,&#xD;
      including basic demographics, medical history, and treatment history.&#xD;
&#xD;
      During the Devolution Visit, results of the tumor BRCA test will be communicated to the&#xD;
      patient, and information about counselling approach and treatment plan will be recorded in&#xD;
      the medical chart. This Devolution Visit will be the last visit for this study for the cases&#xD;
      of non-mutated patients. For patients for whom a BRCA mutation have been identified in tumor,&#xD;
      additional test in blood looking for the specific point mutation found in tumor will be&#xD;
      performed to investigate if these patients harbor a germline BRCA mutation. For these&#xD;
      patients a further visit will be organised to communicate results to the patient and data&#xD;
      regarding germline test results will be recorded in the medical chart of the patient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 27, 2016</start_date>
  <completion_date type="Actual">June 30, 2019</completion_date>
  <primary_completion_date type="Actual">June 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of BRCA 1 and BRCA 2 mutations in newly diagnosed ovarian cancer patients from Latinoamerican population</measure>
    <time_frame>up to one year</time_frame>
    <description>FLABRA is a cross-sectional, multi-center, epidemiological observational study designed to evaluate the prevalence of BRCA mutations in newly diagnosed ovarian cancer patients across understudied ethnic groups in Latin America</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of somatic and germline BRCA 1 and 2 mutations across Latinamerican population</measure>
    <time_frame>up to one year</time_frame>
    <description>To estimate the prevalence of gBRCAm in newly diagnosed ovarian cancer patients who have a BRCA mutation identified in the tumor sample, in LATAM population, and by ethnic sub-groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Counselling approach in ovarian cancer across Latinamerican countries</measure>
    <time_frame>up to one year</time_frame>
    <description>To describe all professionals participating in this process, and time for the approach</description>
  </secondary_outcome>
  <enrollment type="Actual">471</enrollment>
  <condition>Ovarian Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Archived tumor blocks or twenty 10-µm sections from eligible patients will be requested from&#xD;
      the local pathology lab and used for BRCA mutations testing.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Newly diagnosed patients with (FIGO) stage III or IV ovarian epithelial, primary&#xD;
        peritoneal, or fallopian tube cancer made&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclussion criteria:&#xD;
&#xD;
          1. Be able and willing to sign the informed consent form&#xD;
&#xD;
          2. Be older than 18 years of age&#xD;
&#xD;
          3. Have histologically confirmed new diagnosis of Federation of Gynecology and Obstetrics&#xD;
             stage III or IV ovarian epithelial, primary peritoneal, or fallopian tube cancer made&#xD;
             by one or more of the following:&#xD;
&#xD;
               -  standard staging laparotomy including bilateral salpingo-oophorectomy,&#xD;
                  omentectomy, and lymph node sampling and debulking and or&#xD;
&#xD;
               -  surgical resection and radiographic evidence consistent with Stage 3 or 4 ovarian&#xD;
                  cancer&#xD;
&#xD;
               -  paracentesis or biopsy with radiographic evidence consistent with Stage III or IV&#xD;
                  ovarian cancer (normal appearing pancreas, liver, and gastrointestinal tract)&#xD;
&#xD;
          4. Have availability of paraffin-embedded archived tumor tissue block (preferred) or, if&#xD;
             a block is not possible, a minimum of twenty 10 microm sections&#xD;
&#xD;
          5. Have a diagnosis that is within 120 days of informed consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Have a diagnosis of any severe acute or chronic medical or psychiatric conditions that&#xD;
             may increase the risk associated with study participation or may interfere with the&#xD;
             interpretation of the study results and, in the judgement of the Investigator, would&#xD;
             make the patient inappropriate for enrollment in this study&#xD;
&#xD;
          2. Be a patient who, in the judgement of the Investigator, would be inappropriate for&#xD;
             enrollment in this study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1118AAT</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1431FWO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Caba</city>
        <zip>C1426ANZ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cordoba</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Rioja</city>
        <zip>5300</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Resistencia</city>
        <zip>3500</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rosario</city>
        <zip>S2000KZE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barretos</city>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belo Horizonte</city>
        <zip>30130-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Curitiba</city>
        <zip>81520-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fortaleza</city>
        <zip>60336-045</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fortaleza</city>
        <zip>60430-230</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jaú</city>
        <zip>17210-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20560-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>22793-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salvador</city>
        <zip>41950-610</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01246-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>São Paulo</city>
        <zip>01317-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Medellín</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>México</city>
        <zip>1400</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad de Panama</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>0051</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>LIMA 11</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Isidro</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Mexico</country>
    <country>Panama</country>
    <country>Peru</country>
  </location_countries>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D0817R00002&amp;amp;attachmentIdentifier=34f1602d-4fbf-424b-b632-55352d326864&amp;amp;fileName=20200708_FLABRA_CSR_summary.pdf&amp;amp;versionIdentifier=</url>
    <description>CSR Synopsis</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 23, 2016</study_first_submitted>
  <study_first_submitted_qc>December 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2016</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian Cancer</keyword>
  <keyword>BRCA mutations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

